SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001069530-23-000047
Filing Date
2023-09-13
Accepted
2023-09-13 16:17:47
Documents
13
Period of Report
2023-09-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sava-20230908x8k.htm   iXBRL 8-K 85022
2 EX-3.4 sava-20230908xex3_4.htm EX-3.4 121760
  Complete submission text file 0001069530-23-000047.txt   360079

Data Files

Seq Description Document Type Size
3 EX-101.SCH sava-20230908.xsd EX-101.SCH 2656
4 EX-101.LAB sava-20230908_lab.xml EX-101.LAB 15764
5 EX-101.PRE sava-20230908_pre.xml EX-101.PRE 11260
7 EXTRACTED XBRL INSTANCE DOCUMENT sava-20230908x8k_htm.xml XML 4963
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29959 | Film No.: 231252917
SIC: 2834 Pharmaceutical Preparations